{"id":15333,"date":"2023-08-08T23:55:00","date_gmt":"2023-08-08T15:55:00","guid":{"rendered":"https:\/\/flcube.com\/?p=15333"},"modified":"2024-11-27T23:57:38","modified_gmt":"2024-11-27T15:57:38","slug":"johnson-johnson-reaches-settlement-with-fresenius-kabi-and-formycon-ag-for-stelara-biosimilar","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=15333","title":{"rendered":"Johnson &amp; Johnson Reaches Settlement with Fresenius Kabi and Formycon AG for Stelara Biosimilar"},"content":{"rendered":"\n<p>US pharmaceutical giant Johnson &amp; Johnson (J&amp;J; <a href=\"https:\/\/www.google.com\/finance\/quote\/JNJ:NYSE\">NYSE: JNJ<\/a>) has entered into its latest settlement agreement with Fresenius Kabi and Formycon AG, granting the companies a license to launch their biosimilar version of ustekinumab, FYB202, no later than April 15, 2025. This marks the third agreement signed by J&amp;J with companies developing biosimilars for its auto-immune disease blockbuster Stelara (ustekinumab).<\/p>\n\n\n\n<p><strong>J&amp;J&#8217;s Strategy with Biosimilar Developers<\/strong><br>The deal follows similar agreements signed in May with Amgen, allowing for a launch in January 2025, and with Teva and Alvotech, permitting their biosimilar to launch no later than February 25, 2025. All license deals are subject to the drug firms securing US FDA approvals for their respective products. Stelara, a human monoclonal antibody (mAb) targeting interleukin-12 and interleukin-23, is approved to treat immune-mediated disorders such as moderate-to-severe plaque psoriasis, Crohn\u2019s disease, ulcerative colitis, and active psoriatic arthritis.<\/p>\n\n\n\n<p><strong>Stelara&#8217;s Market Performance and Patent Expirations<\/strong><br>J&amp;J reported total sales for the molecule at USD 9.7 billion in 2022, with a 6% year-on-year growth, accounting for 10% of J&amp;J\u2019s total revenues. The patents protecting Stelara in the US are set to begin expiring from September 2023 onwards. Licensing agreements with biosimilar developers allow J&amp;J to mitigate early biosimilar challenges and reduce the potential costs of expensive court battles.<\/p>\n\n\n\n<p><strong>Formycon&#8217;s Specialized Focus on Biosimilars<\/strong><br>Formycon, a company with a specialist focus on biosimilar development, signed a deal with Fresenius Kabi in February 2023 to provide global commercialization support for their ustekinumab molecule. Formycon\u2019s Chief Business Officer, Nicola Mikulcik, noted that the expectation is for a Biologics License Application (BLA) to be filed for the biosimilar later this year, allowing for a launch within the agreed timeframe.<a href=\"https:\/\/flcube.com\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>US pharmaceutical giant Johnson &amp; Johnson (J&amp;J; NYSE: JNJ) has entered into its latest settlement&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,61],"tags":[150,149,858],"class_list":["post-15333","post","type-post","status-publish","format-standard","hentry","category-company","category-legal-ip","tag-jj","tag-johnson-johnson","tag-nyse-jnj"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Johnson &amp; Johnson Reaches Settlement with Fresenius Kabi and Formycon AG for Stelara Biosimilar - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US pharmaceutical giant Johnson &amp; Johnson (J&amp;J; NYSE: JNJ) has entered into its latest settlement agreement with Fresenius Kabi and Formycon AG, granting the companies a license to launch their biosimilar version of ustekinumab, FYB202, no later than April 15, 2025. This marks the third agreement signed by J&amp;J with companies developing biosimilars for its auto-immune disease blockbuster Stelara (ustekinumab).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=15333\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Johnson &amp; Johnson Reaches Settlement with Fresenius Kabi and Formycon AG for Stelara Biosimilar\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=15333\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-08T15:55:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-27T15:57:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15333#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15333\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Johnson &amp; Johnson Reaches Settlement with Fresenius Kabi and Formycon AG for Stelara Biosimilar\",\"datePublished\":\"2023-08-08T15:55:00+00:00\",\"dateModified\":\"2024-11-27T15:57:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15333\"},\"wordCount\":304,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"J&amp;J\",\"Johnson &amp; Johnson\",\"NYSE: JNJ\"],\"articleSection\":[\"Company\",\"Legal \\\/ IP\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=15333#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15333\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=15333\",\"name\":\"Johnson &amp; Johnson Reaches Settlement with Fresenius Kabi and Formycon AG for Stelara Biosimilar - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-08-08T15:55:00+00:00\",\"dateModified\":\"2024-11-27T15:57:38+00:00\",\"description\":\"US pharmaceutical giant Johnson & Johnson (J&J; NYSE: JNJ) has entered into its latest settlement agreement with Fresenius Kabi and Formycon AG, granting the companies a license to launch their biosimilar version of ustekinumab, FYB202, no later than April 15, 2025. This marks the third agreement signed by J&J with companies developing biosimilars for its auto-immune disease blockbuster Stelara (ustekinumab).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15333#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=15333\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15333#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Johnson &amp; Johnson Reaches Settlement with Fresenius Kabi and Formycon AG for Stelara Biosimilar\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Johnson &amp; Johnson Reaches Settlement with Fresenius Kabi and Formycon AG for Stelara Biosimilar - Insight, China&#039;s Pharmaceutical Industry","description":"US pharmaceutical giant Johnson & Johnson (J&J; NYSE: JNJ) has entered into its latest settlement agreement with Fresenius Kabi and Formycon AG, granting the companies a license to launch their biosimilar version of ustekinumab, FYB202, no later than April 15, 2025. This marks the third agreement signed by J&J with companies developing biosimilars for its auto-immune disease blockbuster Stelara (ustekinumab).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=15333","og_locale":"en_US","og_type":"article","og_title":"Johnson &amp; Johnson Reaches Settlement with Fresenius Kabi and Formycon AG for Stelara Biosimilar","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=15333","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-08-08T15:55:00+00:00","article_modified_time":"2024-11-27T15:57:38+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=15333#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=15333"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Johnson &amp; Johnson Reaches Settlement with Fresenius Kabi and Formycon AG for Stelara Biosimilar","datePublished":"2023-08-08T15:55:00+00:00","dateModified":"2024-11-27T15:57:38+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=15333"},"wordCount":304,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["J&amp;J","Johnson &amp; Johnson","NYSE: JNJ"],"articleSection":["Company","Legal \/ IP"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=15333#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=15333","url":"https:\/\/flcube.com\/?p=15333","name":"Johnson &amp; Johnson Reaches Settlement with Fresenius Kabi and Formycon AG for Stelara Biosimilar - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-08-08T15:55:00+00:00","dateModified":"2024-11-27T15:57:38+00:00","description":"US pharmaceutical giant Johnson & Johnson (J&J; NYSE: JNJ) has entered into its latest settlement agreement with Fresenius Kabi and Formycon AG, granting the companies a license to launch their biosimilar version of ustekinumab, FYB202, no later than April 15, 2025. This marks the third agreement signed by J&J with companies developing biosimilars for its auto-immune disease blockbuster Stelara (ustekinumab).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=15333#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=15333"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=15333#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Johnson &amp; Johnson Reaches Settlement with Fresenius Kabi and Formycon AG for Stelara Biosimilar"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15333","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=15333"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15333\/revisions"}],"predecessor-version":[{"id":15334,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15333\/revisions\/15334"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=15333"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=15333"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=15333"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}